OAM
NRIX icon

Oxford Asset Management’s Nurix Therapeutics NRIX Stock Holding History

Oxford Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-29,952
Closed -$277K – 673
2025
Q3 		$277K Buy
+29,952
New +$311K 0.09% 353

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Oxford Asset Management's NRIX Position: Q4 2025 in Review

Oxford Asset Management sold out of Nurix Therapeutics (NRIX) in Q4 2025, closing a stake of 29,952 shares — an estimated $277K sold.

Oxford Asset Management first reported a position in NRIX in Q3 2025 and held it in 1 quarter. The position peaked at $277K in Q3 2025. 182 funds tracked by Wall St. Rank hold NRIX as of Q4 2025.

  • Oxford Asset Management reported no remaining Nurix Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Oxford Asset Management sold 29,952 Nurix Therapeutics shares in Q4 2025, an estimated $277K.
  • Oxford Asset Management first reported a position in Nurix Therapeutics in Q3 2025 and held it in 1 quarter.
  • Oxford Asset Management's Nurix Therapeutics position peaked at $277K in Q3 2025.
  • 182 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2025.

Based on Oxford Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.